EP4 antagonist alone used at a dose shown to be effective in breast cancer (60) had almost no effect in the implanted PDAC model, likely because of the highly desmoplastic stroma and vascular collapse impeding drug perfusion and diffusion (61). Here, PTGER4 is linked to breast carcinoma.